Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. Read more about Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer.
Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer. Read more about Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer.
Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib? Read more about Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. Read more about Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial.
CD38 as a Novel Immunosuppressive Target in Prostate Cancer. Read more about CD38 as a Novel Immunosuppressive Target in Prostate Cancer.
The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. Read more about The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited.
Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer. Read more about Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer.
A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. Read more about A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer.
One of These Things is Not Like the Others: Targeting ATM-mutant Prostate Cancer. Read more about One of These Things is Not Like the Others: Targeting ATM-mutant Prostate Cancer.
Reply to Yi Sun, Fengxiang Sun, Qiang Wei, Jin Huang, and Ruiqi Duan's Letter to the Editor re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by th Read more about Reply to Yi Sun, Fengxiang Sun, Qiang Wei, Jin Huang, and Ruiqi Duan's Letter to the Editor re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by th
